Basic Information
| LncRNA/CircRNA Name | PCAT1 |
| Synonyms | LPCAT1, AGPAT10, AGPAT9, AYTL2, LPCAT-1, PFAAP3, lpcat, lysoPAFAT, PCAT-1 |
| Region | GRCh38_8:126556323-127419050 |
| Ensemble | ENSG00000253438 |
| Refseq | NR_045262 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | |||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | colorectal cancer |
| ICD-0-3 | C19.9 |
| Methods | qPCR |
| Sample | blood |
| Expression Pattern | up-regulated |
| Function Description | PCAT1 rs2632159 polymorphism increased CRC risk by 1.37-fold and 2.19-fold in the dominant and recessive models, respectively (P = 0.040 and 0.041). When the CRC cases were divided into colon cancer and rectal cancer, we found that this polymorphism affected colon cancer risk under the dominant model (P = 0.022, OR = 1.51) and affected rectal cancer susceptibility under the recessive model (P = 0.009, OR = 3.03). A more pronounced effect was observed in the male subgroup in that PCAT1 rs2632159 SNP increased rectal cancer risk by 3.97-fold (P = 0.017). When PCAT1 rs2632159 was present, epistatic effects were observed with rs1902432 and rs785005 (P = 0.011 and 0.008, respectively). eQTL analysis showed that rs2632159 could influence binding with the transcription factors EBF, LUN-1, and TCF12. |
| Pubmed ID | 31253700 |
| Year | 2019 |
| Title | lncRNA-PCAT1 rs2632159 polymorphism could be a biomarker for colorectal cancer susceptibility |
External Links
| Links for PCAT1 | GenBank HGNC NONCODE |
| Links for colorectal cancer | OMIM COSMIC |